Class Action Lawsuit Filed Against GRAIL, Inc.

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Jun 15 2026

0mins

GRAL-0.73%

Explore Agentic TradingLet AI Trade for You

Source: Globenewswire

Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against GRAIL, Inc., aiming to recover damages for investors who purchased GRAIL securities between May 13, 2025, and February 19, 2026, highlighting investor concerns over potential losses.
False Statement Allegations: The complaint alleges that GRAIL executives made materially false statements regarding the likelihood of achieving significant cancer reduction in the NHS-Galleri trial, concealing adverse facts that misled investors about the company's prospects, which could negatively impact stock prices.
Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by August 4, 2026, to share in any potential recovery from the lawsuit, reflecting the legal system's role in protecting investor rights and interests.
Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that has recovered hundreds of millions for investors, emphasizing its expertise and successful track record in securities fraud class actions, which may enhance investor confidence in the lawsuit's potential outcomes.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on GRAL

Wall Street analysts forecast GRAL stock price to fall

3 Analyst Rating

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 68.950

Low

38.00

Averages

60.86

High

83.71

Current: 68.950

Low

38.00

Averages

60.86

High

83.71

Goldman Sachs

Neutral

initiated

$60

2026-06-05

Reason

Goldman Sachs

Price Target

$60

AI Analysis

2026-06-05

initiated

Neutral

Reason

Goldman Sachs initiated coverage of Grail with a Neutral rating and $60 price target. While the company's Galleri test has had success in penetrating the self-pay market for multi-cancer early detection, there is uncertainty around how the FDA and Centers for Medicare and Medicaid Services will evaluate clinical validity and utility in multi-cancer early detection tests, the analyst tells investors in a research note.

Wolfe Research

Peer Perform

initiated

2026-06-01

Reason

Wolfe Research

Price Target

2026-06-01

initiated

Peer Perform

Reason

Wolfe Research assumed coverage of Grail with a Peer Perform rating and no price target. The company need payor support to scale, says Wolfe, which prefers to monitor Grail's progress toward reimbursement from the sidelines.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GRAL

Unlock Now

About GRAL

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GRAIL Faces Class Action Lawsuit for Securities Fraud

4 hours agoGlobenewswire

Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL and its executives for securities fraud related to the NHS-Galleri cancer trial, resulting in a significant stock drop of 50.55% on February 20, 2026.
Stock Price Plunge: Following the announcement of the NHS-Galleri trial's top-line results on February 19, 2026, GRAIL's stock fell from $101.53 to $50.21, a loss of $51.32 per share, as the trial failed to meet its primary endpoint despite some favorable results.
Legal Basis: The lawsuit is based on Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with investors having until August 4, 2026, to apply to lead the case, indicating a severe impact on investor trust regarding the company's disclosures.
Company Impact: As a company focused on early cancer detection, GRAIL's inability to demonstrate the effectiveness of its NHS-Galleri trial may affect its future financing and market credibility, thereby influencing its business strategy and market positioning.

GRAIL Faces Class Action After Trial Failure

14 hours agoPRnewswire

Severe Market Reaction: GRAIL, Inc. lost over $2.2 billion in market capitalization following the announcement of its NHS-Galleri trial results, with shares plummeting more than 50% the next day, reflecting extreme investor disappointment and a collapse of confidence in the company's future prospects.
Legal Action Initiated: Investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026, and suffered significant losses have filed a securities class action lawsuit, alleging that the company and its executives violated federal securities laws and seeking compensation for their losses.
Trial Design Controversy: The lawsuit focuses on GRAIL's disclosures regarding the NHS-Galleri trial design, accusing the company of misleading investors by creating the false impression that it would significantly reduce late-stage cancer diagnoses, leading to erroneous expectations about the company's future performance.
Ongoing Investigation: Hagens Berman is investigating when GRAIL's management became aware of the need for a longer follow-up period and encourages individuals with knowledge to come forward to assist in the investigation of potential misconduct by the company.